Literature DB >> 7844363

Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States.

J Y Lau1, M Mizokami, J A Kolberg, G L Davis, L E Prescott, T Ohno, R P Perrillo, K L Lindsay, R G Gish, K P Qian.   

Abstract

Serum samples from 139 US patients with chronic hepatitis C virus (HCV) infection were studied using six different genotyping systems, including both molecular and serologic methods, to determine the applicability of these approaches and the prevalence of various HCV subtypes. The concordance of genotyping results based on the various systems (except for core polymerase chain reaction genotyping) was good (93.5%). Subtypes 1a and 1b were prevalent (37.4%). Subtypes 2a (2.2%), 2b (8.6%), and 3a (5.8%) were less common. HCV genotypes could not be determined in 3.4%-16.5% of samples depending on the method used. HCV type 2 was associated with greater histologic activity but lower serum HCV RNA levels (P < .05), whereas type 3 was associated with lower serum alanine aminotransferase levels (P < .05). These data demonstrate a high concordance between HCV genotyping systems and provide a foundation for comparison of genotyping data between studies using different systems. HCV types 1a and 1b are both prevalent in the United States.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844363     DOI: 10.1093/infdis/171.2.281

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

2.  Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes.

Authors:  E Orito; M Mizokami; T Tanaka; J Y Lau; K Suzuki; M Yamauchi; Y Ohta; A Hasegawa; S Tanaka; M Kohara
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  Comparative evaluation of two serologic typing methods for hepatitis C virus.

Authors:  A Cerino; A Cividini; M Asti; A Lanza; E Silini; M U Mondelli
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Concordance of hepatitis C virus typing methods based on restriction fragment length polymorphism analysis in 5' noncoding region and NS4 serotyping, but not in core PCR or a line probe assay.

Authors:  S Navas; I Castillo; J Martín; J A Quiroga; J Bartolomé; V Carreño
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Genomic and phylogenetic analysis of hepatitis C virus isolates from argentine patients: a six-year retrospective study.

Authors:  J F Quarleri; B H Robertson; V L Mathet; M Feld; L Espínola; M P Requeijo; O Mandó; G Carballal; J R Oubiña
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Determination of genotypes of hepatitis C virus in Venezuela by restriction fragment length polymorphism.

Authors:  F H Pujol; C L Loureiro; M Devesa; L Blitz; K Parra; S Beker; F Liprandi
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

7.  The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellular carcinoma.

Authors:  C Y Tong; R Khan; N J Beeching; W U Tariq; C A Hart; N Ahmad; I A Malik
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

8.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Authors:  J Detmer; R Lagier; J Flynn; C Zayati; J Kolberg; M Collins; M Urdea; R Sánchez-Pescador
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

Review 9.  Chronic liver disease in Aboriginal North Americans.

Authors:  John D Scott; Naomi Garland
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 10.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.